RxDoctor Payments DataLook up a doctor →

Paul Perry, MD

Pulmonary Disease · Tupelo, MSNPI 1689614513

Payments from drug & device makers

$13,391in general payments, 2019–2025

Across 747 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$2K
  • Boehringer Ingelheim$1K
  • Insmed, Inc.$767
  • Harmony Biosciences LLC$758
  • Sanofi$463
  • plus $6K from 42 others

What the payments were for

  • Travel & lodging$60%
  • Food & beverage$13,22899%
  • Education$1571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,391 in reported general payments places this provider in the 75th percentile of 101 pulmonary disease providers in Mississippi.

See all pulmonary disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$189,826
Medicare patients
1,013
Services billed
3,274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate41$497,979
UptraviSelexipag13$350,054
Trelegy ElliptaFluticasone/Umeclidin/Vilanter478$332,494
Prolastin CAlpha-1-Proteinase Inhibitor12$90,551
Breztri AerosphereBudesonide/Glycopyr/Formoterol131$85,256
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr152$84,858
Dupixent PenDupilumab15$57,329
Ambrisentan15$43,333
NucalaMepolizumab11$39,891
Breo ElliptaFluticasone/Vilanterol74$32,149
Combivent RespimatIpratropium/Albuterol Sulfate45$23,679
Spiriva RespimatTiotropium Bromide34$18,648
Albuterol Sulfate HfaAlbuterol Sulfate515$14,538
Bevespi AerosphereGlycopyrrolate/Formoterol Fum25$11,381
SymbicortBudesonide/Formoterol Fumarate38$11,156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Combivent Respimat, Spiriva Respimat, Stiolto Respimat$1,296$550,918141 claims
GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Breo Ellipta$1,890$489,393715 claims
Actelion Pharmaceuticals US, Inc.Uptravi$197$350,05413 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$2,246$107,793194 claims
Grifols USA, LLCProlastin C$51$90,55112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 101 pulmonary disease providers in Mississippi.

Other pulmonary disease in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →